Sirtinol

Discontinued Product

3521 has been discontinued.

View all Class III HDACs (Sirtuins) products.
说明: Selective sirtuin family deacetylase inhibitor
化学名: 2-[[(2-Hydroxy-1-naphthalenyl)methylene]amino]-N-(1-phenylethyl)benzamide
纯度: ≥98% (HPLC)
说明书
引用文献 (6)
评论
文献 (1)

生物活性 for Sirtinol

Sirtinol is a cell-permeable, selective sirtuin deacetylase inhibitor (IC50 values are 38, 68 and 131 μM at SIRT2, Sir2p and SIRT1 respectively) that has no effect on HDAC1 activity. Significantly decreases growth and viability of PCa and HEK293T cells in vitro.

技术数据 for Sirtinol

分子量 394.47
公式 C26H22N2O2
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 410536-97-9
PubChem ID 5717148
InChI Key YUGODMKHHCZZOI-QJOMJCCJSA-N
Smiles O=C(NC(C)C3=CC=CC=C3)C1=CC=CC=C1/N=C/C2=C(C=CC=C4)C4=CC=C2O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按产品操作查看相关产品

查看全部 Class III HDAC (Sirtuin) Inhibitors

关键词: Sirtinol, Sirtinol supplier, Selective, sirtuin, family, deacetylases, inhibitors, inhibits, Sirtuin, Sir2-like, Family, Class, III, HDACs, (Sirtuins), 3521, Tocris Bioscience

Sirtinol 的评论

目前没有该产品的评论。 Be the first to review Sirtinol and earn rewards!

Have you used Sirtinol?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.